JUBLPHARMA.BOJUBLPHARMA.BOBSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank69
3Y CAGR-9.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-9.7%/yr
vs +18.6%/yr prior
Acceleration
-28.3pp
Decelerating
Percentile
P69
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.59% |
| Q3 2025 | -33.63% |
| Q2 2025 | -11.22% |
| Q1 2025 | 18.87% |
| Q4 2024 | -0.74% |
| Q3 2024 | 2.06% |
| Q2 2024 | -11.72% |
| Q1 2024 | 7.70% |
| Q4 2023 | 9.35% |
| Q3 2023 | -2.90% |
| Q2 2023 | -6.12% |
| Q1 2023 | 2.72% |
| Q4 2022 | 6.24% |
| Q3 2022 | 1.02% |
| Q2 2022 | -2.16% |
| Q1 2022 | 3.11% |
| Q4 2021 | 2.99% |
| Q3 2021 | 2.03% |
| Q2 2021 | 0.45% |
| Q1 2021 | 3.08% |
| Q4 2020 | -13.65% |
| Q3 2020 | 2.18% |
| Q2 2020 | 163.12% |
| Q1 2020 | -61.45% |
| Q4 2019 | 3.15% |
| Q3 2019 | 3.58% |
| Q2 2019 | -13.10% |
| Q1 2019 | 16.11% |
| Q4 2018 | 4.54% |
| Q3 2018 | 5.84% |
| Q2 2018 | -12.59% |
| Q1 2018 | 22.16% |
| Q4 2017 | 14.68% |
| Q3 2017 | 18.85% |
| Q2 2017 | -16.74% |
| Q1 2017 | 20.56% |
| Q4 2016 | 2.57% |
| Q3 2016 | 1.86% |
| Q2 2016 | -8.89% |
| Q1 2016 | 14.67% |